Imipramine for Treatment-Resistant Enuresis, With a Toddler in the House
A 9-year-old has failed both first-line enuresis therapies, and imipramine is the real next step. Whether it's safe to prescribe today turns out to depend less on his own body than on what's within reach of his 18-month-old sister.
Marcus T. is a nine-year-old boy who plays second base for his Little League team and has been lobbying his parents for a dog for at least two years running — the kind of ordinary fourth-grade life that, until recently, had nothing to do with the two therapies he's already tried for a problem neither one has fixed. He wet the bed nearly every night through a fourteen-week alarm course last year — his parents describe waking reliably to the alarm, walking him to the bathroom, and resetting it night after night, without the response ever really taking. More recently, three months of desmopressin brought him down to one or two wet nights a week at its peak, but the improvement drifted back once the dose reached its ceiling. He's socially aware enough now to have stopped accepting sleepover invitations on his own, without his parents having to raise the subject. The family has an 18-month-old daughter, Marcus's sister, who has recently started climbing onto kitchen chairs to reach the counter, and the apartment's medicine storage is a shoebox on top of the refrigerator that nobody has needed to think hard about before, because nothing currently in it is dangerous in a handful of tablets.
Imipramine is the recommended next step for enuresis that hasn't responded to either first-line option — Caldwell and colleagues' Cochrane review of tricyclic and related drugs found a real if modest effect, averaging about one fewer wet night per week across the four placebo-controlled imipramine trials pooled for that outcome, enough to matter for a child who has already been through two therapies that didn't hold. What makes imipramine different from what Marcus has tried so far isn't its efficacy, which is roughly comparable to desmopressin's; it's what a mistake costs. Woolf and colleagues' 2007 consensus guideline for tricyclic poisoning management documents the exact shape of the risk this household would be taking on: a 4-year-old who drank ninety milliliters of a sibling's imipramine syrup, roughly 32mg/kg, and developed ventricular tachycardia and fibrillation four hours later, after an early period that looked deceptively mild. Marcus's sister is younger and lighter than that reported child, in a home where the medicine cabinet is a shoebox on the refrigerator rather than a locked container — and unlike a missed alarm reset or a desmopressin dose that simply stops working, a tricyclic left within a toddler's reach doesn't fail quietly.
Third-line, with a toddler in the apartment
He's failed alarm and failed desmopressin at maximal dose — imipramine is the actual next therapeutic step, not a last resort we're inventing out of desperation. Caldwell's Cochrane synthesis puts a real number on it: about one fewer wet night a week in the pooled placebo-controlled imipramine trials, which for a child already down to one or two nights on desmopressin could plausibly get him the rest of the way. NICE's own guideline permits tricyclic use for exactly this kind of treatment-resistant case, in a specialist-supervised setting — which is what this clinic is. It also tells us what not to pair it with: no anticholinergic alongside imipramine, which rules out the combination we'd otherwise reach for next.
I'd have said the same thing before hearing about the shoebox on the fridge. What changes for me isn't whether to prescribe it — it's what has to happen before the prescription leaves this room.
I want to be precise about why this is different from the other two options he's already tried, because "it didn't work as well as we hoped" and "a toddler drank it" aren't points on the same scale. Woolf's 2007 consensus guideline for tricyclic poisoning documents a 4-year-old who drank ninety milliliters of a sibling's imipramine syrup and was in ventricular fibrillation four hours later — a real reported case, not a theoretical worst case.
My colleague is right that NICE permits tricyclic use in a specialist setting, but the same guideline pairs that permission with an instruction to stress the particular dangers of imipramine overdose to the family, and to store it safely and out of reach of children — and right now this family doesn't have anywhere to put it that a climbing toddler can't reach. I'm not saying never; I'm saying not today, out of this pharmacy, into that kitchen.
Then let's make "not today" into a real plan rather than a stalemate. Before a single tablet is dispensed: a lockbox, purchased and installed, not promised; the pharmacy dispensing one week's supply at a time rather than a full month's bottle, so any single lapse in storage caps the exposure; and a baseline ECG confirming a normal QTc and no conduction abnormality, since imipramine's own cardiac risk concentrates in patients who already have one. If all three are in place at the next visit, I'll write the prescription myself. The toddler isn't a reason to rule this out permanently — she's a reason to make the safeguards real instead of assumed.
Agreed: imipramine not started today; a concrete three-part safeguard plan (secure lockbox, weekly dispensing, baseline ECG) required before the prescription is written; desmopressin continued alone in the interim rather than leaving a treatment gap, with an anticholinergic add-on explicitly excluded from the eventual imipramine plan.
Not agreed: how long to wait if the family can't arrange all three safeguards quickly — the toxicologist wants an indefinite hold until every condition is independently verified, the urologist worries an open-ended delay leaves a child who has already failed two therapies with no realistic next step, and wants a defined re-review date on the calendar regardless of what's confirmed by then.